Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals: Week 96 Results of the Phase 3 BRIGHTE Study - Sorbonne Université Access content directly
Journal Articles The Lancet HIV Year : 2020

Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals: Week 96 Results of the Phase 3 BRIGHTE Study

No file

Dates and versions

hal-03793481 , version 1 (01-10-2022)

Identifiers

Cite

Max Lataillade, Jacob P Lalezari, Michael Kozal, Judith A Aberg, Gilles Pialoux, et al.. Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals: Week 96 Results of the Phase 3 BRIGHTE Study. The Lancet HIV, 2020, 7 (11), pp.e740-e751. ⟨10.1016/S2352-3018(20)30240-X⟩. ⟨hal-03793481⟩
9 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More